CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

M-Protein Detection and Isotyping by MALDI-TOF Mass Spectrometry (MASS-FIX) (CPT 0077U)

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyM-Protein Detection and Isotyping by MALDI-TOF Mass Spectrometry (MASS-FIX) (CPT 0077U)

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionWhen submitting CPT 0077U, file one of the listed covered ICD-10-CM diagnosis codes to support medical necessity for covered indications; verify member-specific benefits and contract exclusions prior to ordering/testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes.

1Primary CPT code covered

6Required ICD-10 diagnoses listed

1Not-covered indication (screening)

Coverage Summary

Policy governs clinical coverage of serum/urine mass spectrometry (MALDI-TOF MS, MASS-FIX) for detection, isotyping, confirmation, and monitoring of monoclonal gammopathies for Medicare Advantage and commercial products, and specifies covered CPT and required ICD-10 diagnoses. The policy specifically covers CPT 0077U when filed with the listed ICD-10 diagnoses. Coverage stance: mixed — MS is covered for certain diagnostic and monitoring indications but excluded for screening.

Medical Necessity / Coverage Criteria

Medically Necessary Uses (Medicare Advantage and Commercial Products)

Covered when the following covered indications are present and filed with a covered ICD-10 diagnosis:

ANY of the following

To confirm a serum protein electrophoresis (SPEP) or serum free light-chain (sFLC) abnormality
To discriminate between therapeutic monoclonal antibodies and endogenous M-proteins
For monitoring: treatment response assessment per guidelines

General Applicability / Benefit Variation

Benefit applicability depends on subscriber contract language

Benefits may vary between groups and contracts; refer to member Benefit Booklet, Evidence of Coverage, or subscriber agreement for laboratory testing benefits/coverage

Some self-funded groups may have contract exclusions per the Biomarker Testing Mandate; check contract-specific coverage and related Genetic/PLA policies

Not Covered Indications

Not Covered

MS is not covered for screening for monoclonal gammopathies

Mass spectrometry (MALDI-TOF MS / MASS-FIX) for screening for MGs

Guideline support notes that the CAP/AACC/ASCP collaborative guideline and the IMWG acknowledge mass spectrometry as an alternative to serum immunofixation electrophoresis (sIFE) to confirm a SPEP or sFLC abnormality, but the guidelines specifically recommend against MS for screening.

Provider Actions & Billing Guidance

Documentation Required

File Covered Indication with Claim

When submitting CPT 0077U, file one of the listed covered ICD-10-CM diagnosis codes to support medical necessity for covered indications.

Affected code: 0077U
File one of the listed ICD-10-CM codes: C88.0; C90.00; C90.01; C90.02; D47.2; E85.81

Documentation Required

Check Contract-Specific Benefits

Verify member-specific benefits and any contract exclusions prior to ordering or testing.

Benefits may vary by group/contract — check the member Benefit Booklet, Evidence of Coverage, or Subscriber Agreement.
Some self-funded groups may have contract exclusions per the Biomarker Testing Mandate; confirm whether the member's plan excludes expanded biomarker/genetic/PLA coverage.

Verify member-specific laboratory testing benefits and any contract exclusions by checking the member’s Benefit Booklet, Evidence of Coverage, or subscriber agreement before ordering or submitting CPT 0077U.

Background & Definitions

Monoclonal gammopathies encompass a spectrum from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma and AL amyloidosis. Traditional detection uses serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (sIFE), and serum free light-chain (sFLC) testing. MALDI-TOF mass spectrometry (MASS-FIX) combines nanobody enrichment of immunoglobulins with MALDI-TOF MS and can detect, isotype, and in some studies quantify M-proteins with higher analytical sensitivity in certain settings and help distinguish therapeutic monoclonal antibodies from endogenous M-proteins.

Term	Definition
MASS-FIX	Nanobody enrichment of immunoglobulins followed by MALDI-TOF mass spectrometry to detect and isotype M-proteins.
M-protein	Monoclonal immunoglobulin protein produced by a single clone of plasma cells; may be intact immunoglobulin or light chain only.

CPT 0077U (Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine; including isotype) is referenced as covered when filed with one of the listed ICD-10-CM diagnosis codes (C88.0, C90.00, C90.01, C90.02, D47.2, E85.81).

Type	Number	Name	Effective Date
LCD	L39189	Mass Spectrometry (MS) Testing in Monoclonal Gammopathy (MG)
NCD	458921	Local Coverage Article: Coding: Mass Spectrometry Testing in Monoclonal Gammopathy (MG)